Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older

被引:20
作者
Ackerson, Bradley [1 ]
Qian, Lei [1 ]
Sy, Lina S. [1 ]
Bruxvoort, Katia [1 ]
Wu, Jun [1 ]
Luo, Yi [1 ]
Diaz-Decaro, John [2 ]
Talarico, Carla [3 ]
Tseng, Hung Fu [1 ]
机构
[1] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA
[2] GlaxoSmithiKline, Rockville, MD USA
[3] Moderna, Rockville, MD 20854 USA
关键词
Herpes zoster; Vaccine; Adults; Series completion; HERPES-ZOSTER; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; SUBUNIT VACCINE; RECOMMENDATIONS; EFFICACY;
D O I
10.1016/j.vaccine.2020.12.076
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: In 2017, a new adjuvanted recombinant zoster vaccine (RZV) was recommended for adults >= 50 years as two-dose series 2-6 months apart. We evaluated two-dose RZV completion and factors associated with completion. Methods: The study included Kaiser Permanente Southern California members >= 50 years who received an RZV dose during April-November 2018 and had continuous membership 12 months before to 9 months after the first RZV dose. Completion was defined as receipt of the second dose >= 4 weeks to 9 months after the first dose (allowing 3-month grace period). Characteristics including age, sex, race/ethnicity, Medicaid status, neighborhood level income and education, comorbidities, history of zoster, health care utilization before and after the first dose, receipt of influenza vaccine, vaccination month (supply short-age proxy), concomitant vaccine, medical center, and medically attended reactions, pain, or gout after the first dose were compared between completers and non-completers. Adjusted odds ratios and 95% confidence intervals for factors associated with completion were estimated by multivariable logistic regression. Results: Among 31,120 first dose recipients, 67.2% completed the series within 9 months. In adjusted analyses, higher completion was associated with White compared with Black or Hispanic race/ethnicity, higher neighborhood income and education, no chronic pulmonary disease, diabetes, or dementia, more outpatient visits and fewer emergency department visits before or after the first dose, no hospitalizations after the first dose, receipt of influenza vaccine, receipt of the first dose in June-November rather than April-May 2018, and no concomitant vaccine with the first dose. Systemic reactions or pain after the first dose was not associated with completion. Conclusion: Completion of RZV series appears suboptimal in the early phase of implementation. Despite similar accessibility in a health care system, completion varied by race/ethnicity, socioeconomic status, health status, and care seeking behavior, suggesting areas to target for improvement. (C) 2021 Elsevier Ltd. All rights reserved.
引用
收藏
页码:926 / 932
页数:7
相关论文
共 29 条
[1]  
[Anonymous], MMWR RECOMM REP
[2]   Why are older adults and individuals with underlying chronic diseases in Germany not vaccinated against flu? A population-based study [J].
Boedeker, Birte ;
Remschmidt, Cornelius ;
Schmich, Patrick ;
Wichmann, Ole .
BMC PUBLIC HEALTH, 2015, 15
[3]   Failure to vaccinate medicare inpatients - A missed opportunity [J].
Bratzler, DW ;
Houck, PM ;
Jiang, H ;
Nsa, W ;
Shook, C ;
Moore, L ;
Red, L .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (20) :2349-2356
[4]   Meeting the Challenges of Immunizing Adults [J].
Bridges, Carolyn B. ;
Hurley, Laura P. ;
Williams, Walter W. ;
Ramakrishnan, Aparna ;
Dean, Anna K. ;
Groom, Amy V. .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2015, 49 (06) :S455-S464
[5]   Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older [J].
Cunningham, A. L. ;
Lal, H. ;
Kovac, M. ;
Chlibek, R. ;
Hwang, S. -J. ;
Diez-Domingo, J. ;
Godeaux, O. ;
Levin, M. J. ;
McElhaney, J. E. ;
Puig-Barbera, J. ;
Abeele, C. Vanden ;
Vesikari, T. ;
Watanabe, D. ;
Zahaf, T. ;
Ahonen, A. ;
Athan, E. ;
Barba-Gomez, J. F. ;
Campora, L. ;
de Looze, F. ;
Downey, H. J. ;
Ghesquiere, W. ;
Gorfinkel, I. ;
Korhonen, T. ;
Leung, E. ;
McNeil, S. A. ;
Oostvogels, L. ;
Rombo, L. ;
Smetana, J. ;
Weckx, L. ;
Yeo, W. ;
Heineman, T. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11) :1019-1032
[6]   Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines [J].
Dooling, Kathleen L. ;
Guo, Angela ;
Patel, Manisha ;
Lee, Grace M. ;
Moore, Kelly ;
Belongia, Edward A. ;
Harpaz, Rafael .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (03) :103-108
[7]   Pain and its persistence in herpes zoster [J].
Dworkin, RH ;
Portenoy, RK .
PAIN, 1996, 67 (2-3) :241-251
[8]   Barriers to health care access among the elderly and who perceives them [J].
Fitzpatrick, AL ;
Powe, NR ;
Cooper, LS ;
Ives, DG ;
Robbins, JA .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2004, 94 (10) :1788-1794
[9]  
Hales Craig M, 2014, MMWR Morb Mortal Wkly Rep, V63, P729
[10]  
Harpaz Rafael, 2007, Morbidity and Mortality Weekly Report, V57, P1